Compare Medpace Holdings Inc (MEDP) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs VNET Group Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: Medpace Holdings Inc is far larger — about 11.4× VNET Group Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and VNET Group Inc for 16 Days on average.
| MEDP | VNET | |
|---|---|---|
Market Cap | $16.82B | $1.47B |
Volume | 223,093 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $630.19 | $14.03 |
52-Week Low | $393.42 | $5.13 |
Typical Hold Time | 14 Days | 16 Days |
Enterprise Value | $16.44B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
VNET Group trades at $5.17, down 4.08% today and near 52-week lows. The technical picture is bearish with negative moving average signals, though RSI indicators suggest potential oversold conditions. Fundamentally, the company shows revenue growth but significant losses with a -22.18% net income margin and negative ROE of -46.49%. Recent strategic investments and AI infrastructure partnerships provide growth catalysts amid financial challenges.
The outlook remains challenging with persistent losses and high leverage, though analyst sentiment leans bullish (62.5% buy ratings). Key risks include balance sheet pressures and execution uncertainty around new partnerships. The stock offers speculative appeal for investors betting on AI infrastructure demand recovery, but requires careful risk management given current financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
